Domestic drug makers' rush to antihypertensive and antidiabetic drugs market

Published: 2004-09-02 07:00:00

Updated: 2004-09-02 07:00:00

Stimulated by the government policy to provide preferential treatment for generic and bioequivalence-tested drugs, a number of drug makers are rushing to introduce generic versions of Pfizer's Novarsc and Handok Pharm's Amaryl in the hope of acquiring large share of the off-patent drugs market.
...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK